On June 17, 2025, Monopar Therapeutics held its Annual Meeting where stockholders elected directors, approved executive compensation, set future advisory vote frequency to once a year, and ratified BPM LLP as the independent auditor for 2025, with 5,048,394 shares represented in the vote.